Gabapentin vs Cyclobenzaprine: side effects in FDA adverse event reports
At a glance
| Gabapentin | Cyclobenzaprine | |
|---|---|---|
| Drug class | – | – |
| Brand names | – | Cyclobenzaprine Hydrochloride |
| FAERS reports | 362,501 | 49,555 |
| Serious | 63% | 68% |
| Death outcome | 34,219 | 7,144 |
| Boxed warning | No | No |
Signals both drugs share
| Reaction | Gabapentin | Cyclobenzaprine | Label screen (A / B) |
|---|---|---|---|
| End stage renal disease | 1,930 · PRR 6.7 | 725 · PRR 17.3 | Not in label — unassessed / Not in label — unassessed |
| Nephrogenic anaemia | 1,020 · PRR 15.9 | 439 · PRR 43.8 | Not in label — unassessed / Not in label — unassessed |
| Temperature regulation disorder | 311 · PRR 9.4 | 461 · PRR 113.1 | Not in label — unassessed / Not in label — unassessed |
| Hyperparathyroidism secondary | 524 · PRR 14.9 | 235 · PRR 43.2 | Not in label — unassessed / Not in label — unassessed |
| Rebound acid hypersecretion | 490 · PRR 10.8 | 241 · PRR 36.0 | Not in label — unassessed / Not in label — unassessed |
| Chronic kidney disease-mineral and bone disorder | 268 · PRR 18.9 | 121 · PRR 53.5 | Not in label — unassessed / Not in label — unassessed |
Labeled signals distinctive to Gabapentin
- Infusion site pain — n=1,220, PRR 6.0 Labeled (related wording)
- Infusion site erythema — n=754, PRR 5.7 Labeled (related wording)
- Infusion site swelling — n=569, PRR 5.8 Labeled (related wording)
- Suspected suicide — n=441, PRR 5.8 Labeled (related wording)
- Infusion site infection — n=232, PRR 6.5 Labeled (related wording)
- Accidental death — n=229, PRR 8.0 Labeled (related wording)
Labeled signals distinctive to Cyclobenzaprine
- None stood out among the strongest labeled signals.
Common questions
Which has more reported side effects, Gabapentin or Cyclobenzaprine?
Gabapentin has 362,501 FAERS reports and Cyclobenzaprine 49,555. More reports does not mean more dangerous: volume follows how widely and how long a drug has been used, prescription vs over-the-counter status, and publicity. The seriousness share (63% vs 68%) is a better like-for-like signal of the kind of problems reported.
Which side effects do Gabapentin and Cyclobenzaprine share?
Both drugs carry disproportionality signals for end stage renal disease, nephrogenic anaemia, temperature regulation disorder, hyperparathyroidism secondary, rebound acid hypersecretion. Shared signals often reflect a shared drug class or the condition both are used for.
Is Gabapentin or Cyclobenzaprine safer?
FAERS cannot answer that: it has no denominator and no comparator. Use this page to see which risks are already on each label and which signals are unlabeled, then check the prescribing information and your clinician for your situation.
Sources: openFDA FAERS pair statistics (OpenPV build 2026-09-14), FDA labels via openFDA, openFDA count queries for seriousness and deaths. Pair chosen because it is a commonly searched comparison. Generated 2026-10-08.